TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15894901

Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme (4-month duration)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Number of subjects: 241
Study: 10598211

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 8590519

Group type: EXPERIMENTAL
Intervention: 3-week intensive treatment program (n = 55)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Untreated control group (n = 51)
Number of subjects: 106
Study: 1770472

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Patient education programme (two educational talks and one tutorial meeting)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control Group (CG) - No patient education programme
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 287
Study: 6751116

Group type: EXPERIMENTAL
Intervention: Praziquantel 60 mg/kg body weight in three divided doses orally
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 11
Study: 31568119

Group type: EXPERIMENTAL
Intervention: Preset telephone alarm
Number of subjects: 79

Group type: COMPARATOR
Intervention: No alarm
Number of subjects: 79
Study: 30537752

Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Tai Chi (VRTC) exercise program, conducted twice weekly for 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Tai Chi (VRTC) exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 27236286

Group type: EXPERIMENTAL
Intervention: Interleaved teaching method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Massed teaching method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interleaved method for first-year students
Number of subjects: 40

Group type: COMPARATOR
Intervention: Massed method for first-year students
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interleaved method for second-year students
Number of subjects: 40

Group type: COMPARATOR
Intervention: Massed method for second-year students
Number of subjects: 40
Study: 24628747

Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen (5 mg/500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Codeine/acetaminophen (30 mg/300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Codeine/acetaminophen
Number of subjects: 0
Study: 22525654

Group type: EXPERIMENTAL
Intervention: Experimental Protocol (EP) - Resistance exercise session with 3 sets of 8 to 10 repetitions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Protocol (CP) - Same procedures as EP but without exercises
Number of subjects: 30
Study: 20071560

Group type: EXPERIMENTAL
Intervention: Metformin (2,000 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Exercise (40 min at 65% Vo(2peak))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metformin + Exercise
Number of subjects: 16
Study: 17905017

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IDUS
Number of subjects: 40
Study: 16085529

Group type: EXPERIMENTAL
Intervention: Menthol cigarettes
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Nonmenthol cigarettes
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Overall tobacco exposure measures
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Gender x race x menthol interaction
Number of subjects: 307
Study: 12107206

Group type: EXPERIMENTAL
Intervention: im T enanthate 100 mg/wk plus daily oral placebo (T)
Number of subjects: 32

Group type: COMPARATOR
Intervention: im placebo/wk plus 125 microg daily oral levonorgestrel (LNG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: im T enanthate 100 mg/wk plus 125 microg daily oral LNG (T + LNG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: im placebo/wk plus daily oral placebo
Number of subjects: 32
Study: 10053098

Group type: EXPERIMENTAL
Intervention: rhuIL‐6 plus G‐CSF
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus G‐CSF
Number of subjects: 50
Study: 8821076

Group type: EXPERIMENTAL
Intervention: Infusion-tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion-capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion-infusion
Number of subjects: 0
Study: 2286454

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g p.o. each on the evening before and after the operation)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30247316

Group type: EXPERIMENTAL
Intervention: QFN-CMV directed valganciclovir prophylaxis (5-11 months post-LTx)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Fixed-duration valganciclovir prophylaxis (5 months)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: QFN-CMV directed valganciclovir prophylaxis (5 months)
Number of subjects: 118

Group type: COMPARATOR
Intervention: No protective immunity (negative QFN-CMV assay)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ceasing antiviral prophylaxis at 11 months with negative assay
Number of subjects: 118
Study: 27696628

Group type: EXPERIMENTAL
Intervention: HD-ARM1 vs HD-ARM2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HD-ARM1 vs HD-ARM3
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HD-ARM1 vs HR-ARM
Number of subjects: 36
Study: 25528977

Group type: EXPERIMENTAL
Intervention: Combination of health worker training, adolescent-friendly facility improvements, and broad information dissemination via community, schools, and mass media.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Demand-generation activities.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Parental and community gatekeepers' approval of SRHS for adolescents.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Out-of-facility-based strategies delivered through mixed-use youth centers.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adolescent friendliness training for health workers.
Number of subjects: 21
Study: 23561918

Group type: EXPERIMENTAL
Intervention: Stenting of saphenous vein grafts (SVGs)
Number of subjects: 80
Study: 21719756

Group type: EXPERIMENTAL
Intervention: Continuous schedule (daily coverage by a single intensivist in half-month rotations)
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Interrupted schedule (weekday coverage by a single intensivist with weekend cross-coverage by colleagues)
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Continuous schedule
Number of subjects: 1900
Study: 19748319

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b 250 microg subcutaneously every other day for 2 years (early treatment)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo (delayed treatment)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Both groups (early and delayed treatment)
Number of subjects: 468
Study: 17845658

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study: 25696357

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice-daily plus dietary counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary counselling alone
Number of subjects: 0
Study: 11483172

Group type: EXPERIMENTAL
Intervention: Naming pictures in the context of same-category items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naming words in the context of same-category items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Producing words with their corresponding determiner
Number of subjects: 0
Study: 9773735

Group type: COMPARATOR
Intervention: Premeal human regular insulin before lunch and supper at unchanged dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Premeal lispro (unchanged dose) at lunchtime and dinner
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pre‐lunch reduced‐dose lispro (70%) before lunch and supper with supplemental lunchtime NPH and with a 6‐h interval until dinner
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pre‐lunch reduced‐dose lispro (70%) before lunch and supper with supplemental lunchtime NPH and with a 8‐h interval until dinner
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Usual‐dose lispro alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reduced‐dose lispro plus NPH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lispro plus NPH
Number of subjects: 12
Study: 7848900

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg i.v.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diltiazem (10 mg i.v.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atenolol (50 or 100 mg/day)
Number of subjects: 30
Study: 3136828

Group type: EXPERIMENTAL
Intervention: Single instillation of 40 mg mitomycin C in 40 ml of water
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Multiple instillations of mitomycin C (single instillation plus four further instillations)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group (no instillation of mitomycin C)
Number of subjects: 457
Study: 31840286

Group type: EXPERIMENTAL
Intervention: Medical smartphone app
Number of subjects: 293

Group type: COMPARATOR
Intervention: Traditional booklet-based and verbal instructions (Control)
Number of subjects: 293
Study: 29549243

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High cereal fiber diet (HCF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moderately increased cereal fiber and protein diet (MIX)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 72
Study: 28657529

Group type: EXPERIMENTAL
Intervention: D-002 (50 mg once daily for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GS/CS (375/300 mg once daily for 12 weeks)
Number of subjects: 60
Study: 25555621

Group type: EXPERIMENTAL
Intervention: BNT+XR-NTX
Number of subjects: 125

Group type: COMPARATOR
Intervention: BNT+placebo injection
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CE+XR-NTX
Number of subjects: 125

Group type: COMPARATOR
Intervention: CE+placebo injection
Number of subjects: 125
Study: 23207887

Group type: EXPERIMENTAL
Intervention: Augmented verbal feedback during countermovement vertical jump (CMVJ) protocol
Number of subjects: 14

Group type: COMPARATOR
Intervention: No feedback during countermovement vertical jump (CMVJ) protocol
Number of subjects: 14
Study: 21939549

Group type: EXPERIMENTAL
Intervention: Chamomile (270 mg twice daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18413195

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 34
Study: 16646124

Group type: EXPERIMENTAL
Intervention: Traumatic brain injury (TBI)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 12544677

Group type: EXPERIMENTAL
Intervention: Oral HRT (equine conjugated estrogens 0.625 mg/day + dydrogesterone 5 mg/day in a continuous combined regimen)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not treated with hormones)
Number of subjects: 80
Study: 10845505

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 42
Study: 8996576

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate combined with cisplatin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Etoposide combined with cisplatin
Number of subjects: 2
Study: 1467031

Group type: EXPERIMENTAL
Intervention: Bicycle ergometer exercise for 20 minutes a day, five days a week for eight weeks at 70%-80% of maximum heart rate
Number of subjects: 22
Study: 30695790

Group type: COMPARATOR
Intervention: Prasugrel (control group)
Number of subjects: 2610

Group type: EXPERIMENTAL
Intervention: Clopidogrel (guided de-escalation group)
Number of subjects: 2610
Study: 29936125

Group type: EXPERIMENTAL
Intervention: Positive psychotherapy for smoking cessation with transdermal nicotine patch and text messaging support
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard behavioral smoking cessation counseling with transdermal nicotine patch and text messaging support
Number of subjects: 340
Study: 26630313

Group type: EXPERIMENTAL
Intervention: Intravitreal conbercept injection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no conbercept)
Number of subjects: 36
Study: 25137875

Group type: EXPERIMENTAL
Intervention: Diabetic specific formula (DSF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 30
Study: 22508825

Group type: EXPERIMENTAL
Intervention: DAC (daunorubicin plus cytarabine plus cladribine)
Number of subjects: 652

Group type: COMPARATOR
Intervention: DAF (daunorubicin plus cytarabine plus fludarabine)
Number of subjects: 652
Study: 20613556

Group type: EXPERIMENTAL
Intervention: Collagen membrane
Number of subjects: 24

Group type: COMPARATOR
Intervention: Polydioxanone (PDS) foil
Number of subjects: 24
Study: 17389691

Group type: EXPERIMENTAL
Intervention: Domino model
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Clements 250 model
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hijazi model
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Clements 125 model
Number of subjects: 58
Study: 15632877

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study: 12227885

Group type: EXPERIMENTAL
Intervention: medrogestone (10 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: dydrogesterone (10 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: medrogestone and dydrogesterone
Number of subjects: 31
Study: 9848597

Group type: EXPERIMENTAL
Intervention: Graft tensioned at 20 N
Number of subjects: 38

Group type: COMPARATOR
Intervention: Graft tensioned at 40 N
Number of subjects: 38
Study: 8090293

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Distal arterial reconstruction (femoro-distal bypass)
Number of subjects: 12
Study: 2806981

Group type: EXPERIMENTAL
Intervention: 20 mg of nalbuphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mg of morphine
Number of subjects: 40
Study: 896016

Group type: EXPERIMENTAL
Intervention: Motor task with the left arm
Number of subjects: 102

Group type: COMPARATOR
Intervention: Motor task with the right arm
Number of subjects: 102
Study: 31260468

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg diluted to 5 ml normal saline)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (5 ml normal saline)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 110
Study: 28414061

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26183669

Group type: EXPERIMENTAL
Intervention: VVSymQ® instrument (patient-reported outcome measure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic daily diary incorporating VVSymQ® instrument
Number of subjects: 0
Study: 24528569

Group type: EXPERIMENTAL
Intervention: Telemedicine (one face-to-face consultation and one via videoconference)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Reference group (two sequential face-to-face consultations)
Number of subjects: 160
Study: 21760497

Group type: EXPERIMENTAL
Intervention: Teleconference support group
Number of subjects: 0
Study: 19539524

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 18246681

Group type: EXPERIMENTAL
Intervention: Three-part massotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Guipi Wan (Pill for Invigorating the Spleen and Nourishing the Heart)
Number of subjects: 200
Study: 14971630

Group type: EXPERIMENTAL
Intervention: Late-luteal phase
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mid-follicular phase
Number of subjects: 15
Study: 15046708

Group type: EXPERIMENTAL
Intervention: Angiogenesis inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metalloproteinase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitors of prostate cancer cell-endothelial cell interactions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 10220667

Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 30
Study: 7799117

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nitrous oxide (N2O)
Number of subjects: 35
Study: 2102144

Group type: EXPERIMENTAL
Intervention: Segmental chemical ablation using 80% phenol
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Segmental chemical ablation using 10% sodium hydroxide
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Post-operative pain
Number of subjects: 422
Study: 7396100

Group type: EXPERIMENTAL
Intervention: Buprenorphine after epidural anaesthesia with diazepam sedation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Buprenorphine after neuroleptanaesthesia
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pentazocine and pethidine after neuroleptanaesthesia
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Buprenorphine after halothane anaesthesia
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pentazocine after halothane anaesthesia
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pentazocine and pethidine after epidural anaesthesia
Number of subjects: 38
Study: 31169125

Group type: EXPERIMENTAL
Intervention: Doxorubicin-loaded nanoparticles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28277235

Group type: EXPERIMENTAL
Intervention: Pediatric radiologist
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Free-standing pediatric hospital (FSPH)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Pediatric 'hospital within a hospital' (PHWH)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Non-pediatric hospital (NPH)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Outpatient radiology facility (ORF)
Number of subjects: 602
Study: 26978413

Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: nimesulide 100 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: diclofenac 100 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg/day
Number of subjects: 80
Study: 25111430

Group type: EXPERIMENTAL
Intervention: Significant-other-enhanced motivational intervention (SOMI)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Individual motivational intervention (IMI)
Number of subjects: 406
Study: 22455403

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (GPT) plus 50 mg sildenafil on-demand
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (GPT) exclusively
Number of subjects: 30

Group type: COMPARATOR
Intervention: 50 mg sildenafil on-demand exclusively
Number of subjects: 30
Study: 19051030

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no octreotide)
Number of subjects: 8
Study: 17559108

Group type: EXPERIMENTAL
Intervention: Drug-eluting nitinol stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study: 15569863

Group type: EXPERIMENTAL
Intervention: Desmoteplase (125 microg/kg)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Desmoteplase (62.5 microg/kg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Desmoteplase (overall)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 104
Study: 11963733

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9804600

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH), end‐tidal PO2 (PETO2) = 55 Torr, PETCO2 held at normal prehypoxic value
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH), PETO2 = 55 Torr
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (C), air breathing
Number of subjects: 10
Study: 7759668

Group type: EXPERIMENTAL
Intervention: Psychosocial treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methodological issues in treatment research
Number of subjects: 0
Study: 2729154

Group type: EXPERIMENTAL
Intervention: Doubly labeled water technique (dlwEE)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Energy expenditure estimated from individual diary records of physical activity
Number of subjects: 6

Group type: COMPARATOR
Intervention: Energy expenditure estimated from 24‐h heart rate recordings
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Average daily energy intake
Number of subjects: 6
Study: 88853

Group type: EXPERIMENTAL
Intervention: Bleomycin therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cryo-surgical treatment
Number of subjects: 55
Study: 31958281

Group type: EXPERIMENTAL
Intervention: SB4, SB2, SB5 (biosimilars of etanercept, infliximab, and adalimumab)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Control group (remission)
Number of subjects: 1265
Study: 31237569

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation mobile app 'Calm' for 8 weeks, participants asked to meditate at least 10 minutes per day.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 88
Study: 28158510

Group type: EXPERIMENTAL
Intervention: Catheter-based renal artery denervation (RDN)
Number of subjects: 1103
Study: 26288230

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176